Two Elderly Patients with Philadelphia Chromosome Positive Mixed Phenotype Acute Leukemia Who Were Successfully Treated with Dasatinib and Prednisolone

Intern Med. 2016;55(9):1177-81. doi: 10.2169/internalmedicine.55.5223. Epub 2016 May 1.

Abstract

Philadelphia chromosome positive (Ph+) mixed phenotype acute leukemia (MPAL) is a rare type of acute leukemia having both myeloid and lymphoid features for which no optimal treatment has yet been established. We herein describe two elderly Ph+MPAL patients who achieved molecular remission without any serious adverse events by treatment with dasatinib and prednisolone. Although dasatinib induction therapy combined with prednisolone is known to be a highly effective treatment for Ph+ acute lymphoblastic leukemia, its efficacy for Ph+MPAL has not been shown. The clinical courses of the present cases suggest that combination therapy with dasatinib and prednisolone is a safe and effective therapeutic modality in elderly Ph+MPAL patients.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Aged
  • Dasatinib / administration & dosage
  • Dasatinib / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Phenotype
  • Philadelphia Chromosome*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Prednisolone / administration & dosage
  • Prednisolone / therapeutic use*
  • Treatment Outcome

Substances

  • Prednisolone
  • Dasatinib